Trial Profile
A 12 Week Phase Ib Randomized Investigator and Subject Blinded Placebo Controlled Repeat-dose Study of LLF580
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs LLF 580 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 25 Aug 2021 Results published in the Journal of Clinical Endocrinology and Metabolism
- 05 Aug 2019 Status changed from recruiting to completed.
- 18 Jul 2019 Planned number of patients changed from 66 to 61.